Effects of third-line chemotherapy for women with recurrent ovarian cancer who received platinum/taxane regimens as first-line chemotherapy

T. Chiyoda, H. Tsuda, H. Nomura, F. Kataoka, E. Tominaga, A. Suzuki, N. Susumu, D. Aoki

Research output: Contribution to journalArticle

8 Citations (Scopus)


Purpose: At present, it remains unclear whether the third-line chemotherapy has clinical benefit. In this study, we retrospectively evaluated the effect of third-line chemotherapy. Methods: We reviewed the medical records of 40 women with recurrent epithelial ovarian cancer (EOC) who received third-line chemotherapy after platinum/taxan regimens as first line chemotherapy. Results: In the first recurrence, 23 cases were platinum-sensitive and 17 cases were platinum-resistant. The cases for which the treatment-free interval from second-line chemotherapy (TFI) was ≥ 3 months had a higher non-PD rate than those with TFI < 3 months (86% vs 33%, p = 0.002). In addition, the median overall survival (OS) was longer for TFI ≥ 3 months than for TFI < 3 months (1195 days vs 235 days, p = 0.004). Finally, TFI was an independent significant prognostic factor by univariate (HR 3.28, p = 0.006) and multivariate (HR 3.21, p = 0.018) proportional hazard tests. Conclusion: TFI from second-line chemotherapy may predict a survival benefit of third-line chemotherapy.

Original languageEnglish
Pages (from-to)364-368
Number of pages5
JournalEuropean Journal of Gynaecological Oncology
Issue number4
Publication statusPublished - 2010



  • Epithelial ovarian cancer
  • Recurrence
  • Third-line chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this